Literature DB >> 25017680

Hypersensitivity reactions to biologic agents.

Alessandra Vultaggio1, Mariana C Castells2.   

Abstract

Biologic agents (BAs) are important therapeutic tools; their use has rapidly expanded and they are used in oncology, immunology, and inflammatory diseases. Their use may be limited, however, by adverse drug reactions. This article reviews the current literature on clinical presentation and pathogenic mechanisms of both acute and delayed reactions. In addition, procedures for management of BA-induced reactions, including preventive and diagnostic work-up, are provided. Lastly, this article summarizes the current knowledge of desensitization to several widely used monoclonal antibodies.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antidrug antibodies; Biologic agents; Drug allergy; Hypersensitivity reactions; Immunogenicity

Mesh：

Substances：

Year:  2014        PMID： 25017680     DOI： 10.1016/j.iac.2014.04.008

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN： 0889-8561            Impact factor:   3.479


  14 in total

Review 1.  [Acute hypersensitivity reactions associated with monoclonal antibodies for targeted therapy].

Authors:  B Sachs; H F Merk
Journal:  Hautarzt       Date:  2018-04       Impact factor: 0.751

Review 2.  Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.

Authors:  Joachim R Kalden; Hendrik Schulze-Koops
Journal:  Nat Rev Rheumatol       Date:  2017-11-21       Impact factor: 20.543

Review 3.  Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.

Authors:  Brian A Baldo
Journal:  Drug Saf       Date:  2015-05       Impact factor: 5.228

4.  Glycan and Peptide IgE Epitopes of the TNF-alpha Blockers Infliximab and Adalimumab - Precision Diagnostics by Cross-Reactivity Immune Profiling of Patient Sera.

Authors:  Arne Homann; Niels Röckendorf; Arno Kromminga; Andreas Frey; Thomas A Platts-Mills; Uta Jappe
Journal:  Theranostics       Date:  2017-10-17       Impact factor: 11.556

Review 5.  Hypersensitivity Reactions to Biologicals: from Bench to Bedside.

Authors:  Aysegul Akarsu; Ozge Soyer; Bulent Enis Sekerel
Journal:  Curr Treat Options Allergy       Date:  2020-01-18

Review 6.  Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers.

Authors:  Teodorikez Wilfox Jimenez-Rodriguez; Marlene Garcia-Neuer; Leila A Alenazy; Mariana Castells
Journal:  J Asthma Allergy       Date:  2018-06-20

7.  Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.

Authors:  A Deodhar; P J Mease; I B McInnes; X Baraliakos; K Reich; A Blauvelt; C Leonardi; B Porter; A Das Gupta; A Widmer; L Pricop; T Fox
Journal:  Arthritis Res Ther       Date:  2019-05-02       Impact factor: 5.156

8.  Virus-like particle display of HER2 induces potent anti-cancer responses.

Authors:  Arianna Palladini; Susan Thrane; Christoph M Janitzek; Jessica Pihl; Stine B Clemmensen; Willem Adriaan de Jongh; Thomas M Clausen; Giordano Nicoletti; Lorena Landuzzi; Manuel L Penichet; Tania Balboni; Marianna L Ianzano; Veronica Giusti; Thor G Theander; Morten A Nielsen; Ali Salanti; Pier-Luigi Lollini; Patrizia Nanni; Adam F Sander
Journal:  Oncoimmunology       Date:  2018-01-05       Impact factor: 8.110

9.  Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform.

Authors:  Josef Singer; Krisztina Manzano-Szalai; Judit Fazekas; Kathrin Thell; Anna Bentley-Lukschal; Caroline Stremnitzer; Franziska Roth-Walter; Margit Weghofer; Mirko Ritter; Kerstin Pino Tossi; Markus Hörer; Uwe Michaelis; Erika Jensen-Jarolim
Journal:  Oncoimmunology       Date:  2016-04-21       Impact factor: 8.110

Review 10.  Drug allergy.

Authors:  Richard Warrington; Fanny Silviu-Dan; Tiffany Wong
Journal:  Allergy Asthma Clin Immunol       Date:  2018-09-12       Impact factor: 3.406
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.